New strategies in the treatment and prevention of allergic diseases

Allergic diseases (AD) are more prevalent today than 30 years ago but over the same period, few novel efficacious drugs have been discovered to treat, control or even cure these disorders.
Topical or systemic glucocorticosteroids combined with symptom-relieving medications, such as ?2-adrenoceptor agonists, leukotriene inhibitors or antihistamines, are still the mainstay of antiallergic treatment. Modified glucocorticosteroids with less adverse effects, better bronchodilators and new selective mediator inhibitors may improve symptom control in the future. Only specific immunotherapy has shown potential for long-lasting disease-modifying effects.
Immunomodulation is a therapeutic goal, aiming to modify the dominant helper T cell Type 2 inflammation to a helper T cell Type 1 response using modified allergens, mycobacteria or CpG oligodeoxynucleotides. Humanised monoclonal anti-IgE antibodies are an exciting new immunomodulatory medication that are expected to reach the clinical practice and have recently been licensed in Australia and the US.
Advances in molecular, cellular and genetic research of the immunopathophysiology of AD have led to the development of new antagonists for cytokines, chemokines, receptors, second messengers and transcription factors that may become available for clinical use in the next 10 years. Specific diets supplemented with antioxidants or probiotics need further study but offer promise as safe and cheap preventative medicine.
The strong genetic component of AD and the Human Genome Project have opened a new field of research, and modification or replacement of target genes has a curative potential with exciting new therapeutic developments in the years ahead.

allergic conjunctivitis, allergic dermatitis, allergic rhinitis, anti-inflammatory, antioxidants, antisense, asthma, atopy, ?2-adrenoceptor, chemokines, cytokines, food allergy, genetics, glucocorticosteroids, histamine, Ige, immunomodulation, immunosuppression, immunotherapy, kinins, leukotrienes, mast cell, mediators, mycobacterium, new agents, nitric oxide, oligodeoxynucleotide, oxidative stress, phosphodiesterase, probiotics, proteases, rna interference, sirna, stem cells, therapy, treatment, urticaria

1354-3784

107-124

http://www.ingentaconnect.com/content/apl/eid/2004...

Haitchi, H.M.

68dadb29-305d-4236-884f-e9c93f4d78fe

Holgate, S.T.

2e7c17a9-6796-436e-8772-1fe6d2ac5edc

2004

Haitchi, H.M.

68dadb29-305d-4236-884f-e9c93f4d78fe

Holgate, S.T.

2e7c17a9-6796-436e-8772-1fe6d2ac5edc

Haitchi, H.M. and Holgate, S.T. (2004) New strategies in the treatment and prevention of allergic diseases. Expert Opinion on Investigational Drugs, 13 (2), 107-124.

Record type: Article

Abstract

This record has no associated files available for download.

More information

Published date: 2004

Related URLs:

http://www.ncbi.nlm.nih.gov/en...s=14996646

Keywords: allergic conjunctivitis, allergic dermatitis, allergic rhinitis, anti-inflammatory, antioxidants, antisense, asthma, atopy, ?2-adrenoceptor, chemokines, cytokines, food allergy, genetics, glucocorticosteroids, histamine, Ige, immunomodulation, immunosuppression, immunotherapy, kinins, leukotrienes, mast cell, mediators, mycobacterium, new agents, nitric oxide, oligodeoxynucleotide, oxidative stress, phosphodiesterase, probiotics, proteases, rna interference, sirna, stem cells, therapy, treatment, urticaria